Seaport Therapeutics Inc. (SPTX)
NASDAQ: SPTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $966.23M
- EPS (TTM)
- -$4.35
- Dividend yield
- None
- 52-week range
- 14.85 – 28.38
- Day range
- 17.41 – 18.83
- Volume / Avg
- 284.27K / 259.83K
- Beta
- —
- Shares outstanding
- 53.53M
52-week range
SPTX stock today
On Nov 20, SPTX ended the session at $18.05, shedding $0.27 (1.47%), versus the S&P 500's 3.70% decline. Shares are 36.4% below their 52-week high of $28.38, set on Aug 27, 2026 and 21.5% above the 52-week low of $14.85, in the middle of the past year's range. Seaport Therapeutics has posted a net loss over the last twelve months (EPS of -$4.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Seaport Therapeutics
Company profileSeaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Daphne Zohar
- Headquarters
- Boston, MA
- Employees
- 59
- IPO year
- 2026
- Website
- seaporttx.com
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$37.13+105.71%
- Strong buy 1
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $-0.49 vs $-0.58
- Surprise
- +15.52%
SPTX news
All SPTX news- Seaport Therapeutics Reports Positive GlyphAllo Data; GlyphAgo Phase 2a Trial UnderwayNasdaqSPTX, SUN
- Seaport Therapeutics, Inc. GAAP EPS of -$0.49 beats by $0.09Seeking Alpha
- Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressBusiness Wire
- Canaccord Genuity Initiates Coverage of Seaport Therapeutics with Buy RatingNasdaq
Seaport Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OMEROmeros Corporation | 13.21 | -5.71% | $983.66M | vs SPTX |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs SPTX |
| ANROAlto Neuroscience Inc. | 25.37 | -4.30% | $1.02B | vs SPTX |
| MLTXMoonLake Immunotherapeutics Class A | 11.07 | +0.36% | $942.13M | vs SPTX |
| SVRASavara Inc. | 4.26 | -18.23% | $939.86M | vs SPTX |
| CTYCity Therapeutics Inc. | 19.32 | +5.29% | $1.03B | vs SPTX |
| NKTRNektar Therapeutics | 30.20 | -7.19% | $1.03B | vs SPTX |
| JBIOJade Biosciences Inc. | 15.31 | +1.66% | $1.06B | vs SPTX |
Indexes, lists and sector
Seaport Therapeutics stock FAQ
What is Seaport Therapeutics's stock price today?
SPTX last traded at $18.05 as of Nov 20, 4:00 PM EST, down 1.47% on the day. Prices are delayed at least 15 minutes.
Who is Seaport Therapeutics's CEO?
Ms. Daphne Zohar is the chief executive officer of Seaport Therapeutics Inc., which has about 59 employees.
What is the SPTX 52-week high?
The 52-week high for SPTX is $28.38 and the 52-week low is $14.85. The stock is currently 36.4% below its high.